Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK3 | P52333 | 19/20 | 0.64 |
| ▸ | JAK2 | O60674 | 17/20 | 0.64 |
| ▸ | JAK1 | P23458 | 11/20 | 0.64 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.49 |
| ▸ | TYK2 | P29597 | 4/20 | 0.45 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | PRKCA | P17252 | 1/20 | 0.43 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.43 |
| ▸ | CDK2 | P24941 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.43 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.43 |
| ▸ | MAP3K9 | P80192 | 1/20 | 0.43 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.43 |
| ▸ | CAMK2A | Q9UQM7 | 1/20 | 0.43 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13398383 | 0.88 | JAK3 (0.70) | JAK3JAK2JAK1KCNH2TYK2 | |
| SCHEMBL13398259 | 0.78 | JAK2 (0.55) | JAK3JAK2JAK1KCNH2TYK2 | |
| SCHEMBL2102284 | 0.78 | JAK2 (1.00) | JAK3JAK2JAK1KCNH2 | |
| SCHEMBL10099446 | 0.76 | JAK3 (0.67) | JAK3JAK2JAK1KCNH2TYK2 | |
| SCHEMBL13417609 | 0.76 | JAK2 (0.50) | JAK3JAK2JAK1KCNH2TYK2 | |
| SCHEMBL9918460 | 0.76 | JAK3 (0.60) | JAK3JAK2JAK1KCNH2TYK2 | |
| SCHEMBL9918432 | 0.75 | JAK2 (0.68) | JAK3JAK2JAK1KCNH2TYK2 | |
| SCHEMBL2106026 | 0.73 | JAK2 (0.89) | JAK3JAK2JAK1KCNH2 | |
| SCHEMBL13398354 | 0.73 | JAK3 (0.54) | JAK3JAK2JAK1KCNH2TYK2 | |
| SCHEMBL13398328 | 0.72 | JAK3 (0.61) | JAK3JAK2JAK1KCNH2TYK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | BIOCRYST PHARMACEUTICALS, INC. (US) | 2012-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149662-A1 | Heterocyclic Compounds as Janus Kinase Inhibitors | JAK2, JAK1, JAK3 | JAK3 3/4885JAK2 1/4885JAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.